Pharmacist's Letter Canada

Commentary: Ezetimibe’s Role in Cardiovascular Risk Reduction January 2015

PL Voices: How to Manage Patients Who Don’t Respond Well To Levothyroxine January 2015

PL Voices: Role of Ezetimibe (Zetia, etc) for Dyslipidemia January 2015

PL Voices: Role of New Oral Anticoagulants in Atrial Fibrillation Patients Undergoing Cardioversion December 2014

Guideline: 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation December 2014

Article: Emphasize Daily Adherence With the New Oral Anticoagulants After Cardioversion December 2014

PL Voices: Role of New Oral Anticoagulants for Treatment of Venous Thromboembolism November 2014

Commentary: Diclofenac: Cardiovascular Safety Information and Dose Change November 2014

Article: Suggest Xarelto Over Pradaxa for Treating VTE November 2014

Article: Recommend NOT Going Over 100 mg/day of Diclofenac Orally or Rectally November 2014

Guideline: 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery October 2014

PL Voices: Duration of Treatment of Dual Antiplatelet Therapy October 2014

Commentary: Hormonal Contraceptives and Thrombosis Risk October 2014

Patient Education: What I Need to Know About My Heart Stent Meds October 2014

Chart: Oral Antiplatelets for Stent Patients October 2014

Resources